EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma (deutsch)
Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Schlagwort(e):
Sonstiges
Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic
to conduct a Clinical Trial in Lymphoma
08.06.2023 / 11:31 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Würzburg, Bavaria, 8 June 2023. PentixaPharm GmbH, a developer of innovative
radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from
the German Federal Institute for Drugs and Medical Devices (BfArM) to start
PTT101, its open-label dose escalation study to evaluate the safety,
tolerability, biodistribution and efficacy of PentixaTher. The Yttrium-90
labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic
against recurrent or refractory primary or isolated secondary central
nervous system lymphoma.
The phase I/II, dose-finding study will be conducted at the University
Hospital in Essen, North Rhine Westphalia, Germany. "After showing up to 90%
of CNS lymphoma patients overexpressing the target CXCR4 with the
Ga68-labeled tracer PentixaFor in CNS lymphoma patients, we are happy to
test now the therapeutic impact when attacking CXCR-4 with [90Y]Y-PentixaTher
(yttrium (90Y) anditixafortide). The study will start after getting final
endorsement from the German Radiation Safety Department (BfS)," commented
Dr. Hakim Bouterfa, Chief Medical Officer at Eckert & Ziegler.
In addition, radiolabelled PentixaTher has shown outstanding results under
named-patient programs in patients with T-cell lymphoma as conducted at the
University Hospital Würzburg (DOI: 10.2967/jnumed.122.264207) (1).
1) Buck AK, Grigoleit GU, Kraus S, Schirbel A, Heinsch M, Dreher N, Higuchi
T, Lapa C, Hänscheid H, Samnick S, Einsele H, Serfling SE, Werner RA. C-X-C
Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with
Advanced T-Cell Lymphoma. J Nucl Med. 2023 Jan;64(1):34-39. doi:
10.2967/jnumed.122.264207. Epub 2022 Jun 23. PMID: 35738903; PMCID:
PMC9841250.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000
employees is a leading specialist for isotope-related components in nuclear
medicine and radiation therapy. The company offers a broad range of services
and products for the radiopharmaceutical industry, from early development
work to contract manufacturing and distribution. Eckert & Ziegler shares
(ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
08.06.2023 CET/CEST Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch EQS News - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate
News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter https://eqs-news.com
Sprache: Deutsch
Unternehmen: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Telefon: +49 30 941084-138
Fax: +49 30 941084-112
E-Mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indizes: SDAX, TecDAX
Börsen: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart, Tradegate Exchange
EQS News ID: 1652711
Ende der Mitteilung EQS News-Service
1652711 08.06.2023 CET/CEST
ISIN DE0005659700
AXC0068 2023-06-08/11:32
Relevante Links: Eckert & Ziegler Strahlen- und Medizintechnik AG